Tsuyoshi Kasama

Tsuyoshi Kasama

Auto-generated profile, based on publicly available information

Tsuyoshi Kasama

Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2005 in Current Drug Targets - Inflammation & Allergy
Verified
Journal Article
Closed access
PDF file
TKTsuyoshi Kasama
Tsuyoshi Kasama
YMYusuke Miwa
Yusuke Miwa
TITakeo Isozaki
Takeo Isozaki
TOTsuyoshi Odai
Tsuyoshi Odai
MAMitsuru Adachi
Mitsuru Adachi
SKSteven L. Kunkel
Steven L. Kunkel
Polymorphonuclear neutrophils (PMNs) are usually thought of as the leukocyte population involved in acute inflammatory responses, acting as a first line of defense against invading microorganisms. These terminally differentiated cells are generally not thought of as an important source of de novo synthesis of polypeptide mediators. Recent progress has shown, however, that PMNs are able to synthesize cytokines in response to a variety of inflammatory stimuli and during certain pathological conditions. The expression profiles of PMN-derived cytokines are similar with those of monocytes/macrophages, major professional phagocytes. Like monocytes, PMNs are able to secrete proinflammatory cytokines [e.g., tumor necrosis factor (TNF)-α and interleukin (IL)-1β], both CC and CXC chemokines [e.g., IL-8, interferoninducible protein 10 (IP-10) and macrophage inflammatory protein (MIP)-1α], and angiogenic factors [e.g., vascular endothelial growth factor (VEGF)]. The secretion of cytokines by activated PMNs is regulated by immunoregulatory cytokines such as interferon (IFN)-γ, IL-4, IL-10 and IL-13. In addition to acute inflammatory responses, PMNs and PMN-derived cytokines appear to be involved in the pathogenesis of such chronic inflammatory disorders as rheumatoid arthritis, inflammatory bowel diseases and mycobacterial infections. Conceivably, these findings place PMNs at a pivotal position where they regulate and orchestrate not only acute inflammatory responses but also chronic inflammation and immune regulation. As such, inhibition of PMN-derived cytokines is viewed as a potentially useful strategy for therapeutic immunointervention.

1 June 2000 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
JLJing Lu
Jing Lu
TKTsuyoshi Kasama
Tsuyoshi Kasama
KKKazuo Kobayashi
Kazuo Kobayashi
YYYoshiyuki Yoda
Yoshiyuki Yoda
FSFumitaka Shiozawa
Fumitaka Shiozawa
MAMitsuru Adachi
Mitsuru Adachi
We have examined the expression and function of the angiogenic factor, vascular endothelial growth factor (VEGF) during the evolution of type II collagen-induced arthritis (CIA). Biologically active VEGF was expressed along a time course that paralleled the expression of two specific VEGF receptors, Flk-1 and Flt-1, and the progression of joint disease. Moreover, levels of VEGF expression correlated with the degree of neovascularization, as defined by vWF levels, and arthritis severity. Macrophage- and fibroblast-like cells, which infiltrated inflamed sites and were then activated by other inflammatory mediators, are probably important sources of VEGF and may thus regulate angiogenesis during the development of CIA. Administration of anti-VEGF antiserum to CIA mice before the onset of arthritis delayed the onset, reduced the severity, and diminished the vWF content of arthritic joints. By contrast, administration of anti-VEGF antiserum after the onset of the disease had no effect on the progression or ultimate severity of the arthritis. These data suggest that VEGF plays a crucial role during an early stage of arthritis development, affecting both neovascularization and the progression of experimentally induced synovitis.

6 January 2003 in Arthritis Research & Therapy
Verified
Journal Article
Open access
RHRyosuke Hanaoka
Ryosuke Hanaoka
TKTsuyoshi Kasama
Tsuyoshi Kasama
MMMizuho Muramatsu
Mizuho Muramatsu
NYNobuyuki Yajima
Nobuyuki Yajima
FSFumitaka Shiozawa
Fumitaka Shiozawa
MAMitsuru Adachi
Mitsuru Adachi
Chemokines play an essential role in the progression of rheumatoid arthritis (RA). In the present study we examined the expression and regulatory mechanisms of IFN-gamma inducible protein (IP)-10 in RA synovitis. RA synovial fluid contained greater amounts of IP-10 than did synovial fluid from patients with osteoarthritis. Immunolocalization analysis indicated that IP-10 was associated mainly with infiltrating macrophage-like cells, and fibroblast-like cells in the RA synovium. The interaction of activated leukocytes with fibroblast-like synoviocytes resulted in marked increases in IP-10 expression and secretion. Moreover, induction of IP-10 was mediated via specific adhesion molecules, as indicated by the finding that both anti-integrin (CD11b and CD18) and intercellular adhesion molecule-1 antibodies significantly inhibited IP-10 induction. These results suggest that IP-10 expression within inflamed joints appears to be regulated not only by inflammatory cytokines but also by the physical interaction of activated leukocytes with fibroblast-like synoviocytes, and that IP-10 may contribute to the recruitment of specific subpopulations of T cells (Th1 type) from the bloodstream into the synovial joints.

26 June 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
MSMattias N. D. Svensson
Mattias N. D. Svensson
MZMartina Zoccheddu
Martina Zoccheddu
SYShen Yang
Shen Yang
GNGyrid Nygaard
Gyrid Nygaard
CSChristian Secchi
Christian Secchi
NBNunzio Bottini
Nunzio Bottini
PTPRS-targeted FLS-directed therapy synergizes with TNF inhibition in therapy of arthritis.

2 June 2005 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
NYNobuyuki Yajima
Nobuyuki Yajima
TKTsuyoshi Kasama
Tsuyoshi Kasama
TITakeo Isozaki
Takeo Isozaki
TOTsuyoshi Odai
Tsuyoshi Odai
MMMizuho Matsunawa
Mizuho Matsunawa
MAMitsuru Adachi
Mitsuru Adachi
Objective: To determine levels of the soluble form of the chemokine fractalkine (sFkn) and its receptor, CX3CR1, in patients with systemic lupus erythematosus (SLE) with neuropsychiatric involvement (NPSLE) and in SLE patients without neuropsychiatric involvement, and to assess their relationship with disease activity and organ damage.Methods: Levels of sFkn in serum and cerebrospinal fluid (CSF) were measured by enzyme‐linked immunosorbent assay. Expression of Fkn and CX3CR1 was quantified using real‐time polymerase chain reaction. Surface expression of CX3CR1 on peripheral blood mononuclear cells (PBMCs) was determined by flow cytometry. Disease activity and organ damage were assessed using the SLE Disease Activity Index (SLEDAI) and the Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index, respectively.Results: Serum sFkn levels were significantly higher in patients with SLE than in patients with rheumatoid arthritis (RA) or healthy controls. In addition, significant correlations between serum sFkn levels and the SLEDAI, the SLICC/ACR Damage Index, anti–double‐stranded DNA and anti‐Sm antibody titers, immune complex levels (C1q), and serum complement levels (CH50) were observed. Expression of CX3CR1 was significantly greater in PBMCs from patients with active SLE than in those from RA patients or healthy controls. Levels of sFkn were also significantly higher in CSF from untreated patients with newly diagnosed NPSLE than in SLE patients without neuropsychiatric involvement; treatment reduced both serum and CSF levels of sFkn in patients with SLE.Conclusion: Soluble Fkn and CX3CR1 may play key roles in the pathogenesis of SLE, including the neuropsychiatric involvement. Soluble Fkn is also a serologic marker of disease activity and organ damage in patients with SLE, and its measurement in CSF may be useful for the diagnosis of NPSLE and followup of patients with NPSLE.

30 October 2006 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
MMMizuho Matsunawa
Mizuho Matsunawa
TITakeo Isozaki
Takeo Isozaki
TOTsuyoshi Odai
Tsuyoshi Odai
NYNobuyuki Yajima
Nobuyuki Yajima
HTHiroko T. Takeuchi
Hiroko T. Takeuchi
TKTsuyoshi Kasama
Tsuyoshi Kasama
Objective: To determine levels of soluble fractalkine (sFkn) in rheumatoid arthritis (RA) patients with and without rheumatoid vasculitis (RV), and to assess the relationship of sFkn levels to disease activity.Methods: Serum was obtained from 98 RA patients (54 without vasculitis, 36 with extraarticular manifestations but without histologically proven vasculitis, and 8 with histologically proven vasculitis) and from 38 healthy individuals. Levels of sFkn were measured by enzyme‐linked immunosorbent assay. Expression of Fkn and CX3CR1 was quantified by real‐time polymerase chain reaction. Vasculitis disease activity was assessed using the Birmingham Vasculitis Activity Score and the Vasculitis Activity Index.Results: Serum sFkn levels were significantly higher in patients with RA than in controls and were significantly higher in RA patients with RV than in those without vasculitic complications. Statistically significant correlations were observed between serum sFkn levels in RA patients and levels of C‐reactive protein, rheumatoid factor, immune complex, and complement. In the RV group, sFkn levels also correlated with disease activity. Immunohistochemical analysis indicated that Fkn levels were associated mainly with endothelial cells in vasculitic arteries. In addition, expression of CX3CR1 messenger RNA was significantly greater in peripheral blood mononuclear cells from patients with active RV than in those from other RA patients or controls. Notably, serum sFkn levels were significantly diminished following successful treatment and clinical improvement.Conclusion: These findings suggest that Fkn and CX3CR1 play crucial roles in the pathogenesis of RV and that sFkn may serve as a serologic inflammatory marker of disease activity in RA patients with vasculitis.